You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK)獲授抑鬱症藥物大中華專利
阿思達克 10-13 08:40
麗珠醫藥(01513.HK)公佈,與蘇州蘭晟醫藥簽署《專利及技術轉讓協議》,獲蘭晟授予磷酸二酯(酉每)4(PDE4)抑制劑(LS21031)在大中華區(內地、香港、澳門及臺灣)所有權利、所有權和權益轉讓,需向蘭晟支付相應的專利及技術轉讓費及銷售提成,其中技術轉讓費用總額最高不超過1.65億元人民幣。目標產品在大中華區域內獲批上市銷售後,根據協議需支付全年淨銷售額不低於4%的銷售提成。 LS21031是蘭晟自主研發的一款創新高選擇性磷酸二酯(酉每)4D(PDE4D)變構調節劑,已於今年3月在中國獲批臨牀,適應症爲抑鬱症。現有資料表明,LS21031具有抗抑鬱起效速度快、安全性好等優勢,同時還有改善認知障礙的潛力。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account